nach oben

Clinical Drug Investigation

Erschienen in:

01.12.2005 | Short Communication

Famciclovir for the Management of Genital Herpes Simplex in Patients with Inadequate Response to Aciclovir or Valaciclovir

verfasst von: Stephen L. Sacks, Dr Fred Y. Aoki

Erschienen in: Clinical Drug Investigation | Ausgabe 12/2005

Einloggen, um Zugang zu erhalten

Excerpt

Treatment of herpes simplex virus (HSV) is currently based on the acyclic nucleoside analogues. In HSV-infected cells, these agents are monophosphorylated by viral-encoded thymidine kinase and then converted to their active triphosphate form by cellular enzymes. The triphosphate form, which lacks the 3-hydroxyl group necessary for elongation of the chain during DNA transcription, acts both as a competitive inhibitor for viral DNA polymerase and as a chain terminator, thereby blocking viral replication. …

Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral aciclovir. JAMA 1984; 251: 2103–7PubMedCrossRef

de Miranda P, Blum MR. Pharmacokinetics of aciclovir after intravenous and oral administration. J Antimicrob Chemother 1983; 12Suppl. B: 29–37

Douglas JM, Critchlon C, Benedetti J. A double-blind study of oral acyclovir for the suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984; 310: 1551–6PubMedCrossRef

Kinghorn GR. Long-term suppression with oral aciclovir of recurrent herpes simplex virus infections in otherwise healthy patients. Am J Med 1988; 85Suppl. 2A: 26–9PubMed

Boyd MR, Safrin S, Kern ER. Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antivir Chem Chemother 1993; 4Suppl. 1: 3–11

Boyd MR, Bacon TH, Sutton D, et al. Anti-herpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother 1987; 31: 1238–42PubMedCrossRef

Vere Hodge RA, Perkins RM. Mode of action of 9-(4-hydroxy-3hydroxymethyl but-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother 1989; 33: 223–9CrossRef

Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antivir Chem Chemother 1993; 4Suppl. 1: 47–55

Pue MA, Pratt SK, Fairless AJ, et al. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750mg to healthy volunteers. J Antimicrob Chemother 1994; 33: 119–27PubMedCrossRef

10.

Vere Hodge RA, Darlison SJ, Earnshaw DL, et al. Use of isotopically chiral [4′-13C]penciclovir and 13C NMR to determine the specificity and absolute configuration of penciclovir phosphate esters formed in HSV-1 and HSV-2 infected cells and by HSV-1-encoded thymidine kinase. Chirality 1993; 5: 583–8CrossRef

11.

Sacks SL, Aoki FY, Diaz-Mitoma F, et al. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, double-blind multicenter trial. JAMA 1996; 276: 44–9PubMedCrossRef

12.

Chosidow O, Drouault Y, Leconte-Veyriac F, et al. Famciclovir vs aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-group, randomized, double-blind clinical trial. Br J Dermatol 2001; 144: 818–24PubMedCrossRef

13.

Romanowski B, Aoki FY, Martel AY, et al. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. AIDS 2000; 14: 1211–7PubMedCrossRef

14.

Diaz-Mitoma F, Sibbald RG, Shafran SD, et al. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. JAMA 1998; 280: 887–92PubMedCrossRef

15.

Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: a multicenter, double-blind, placebo-controlled trial. Arch Intern Med 1997; 157: 343–9PubMedCrossRef

16.

Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. Ann Intern Med 1998; 128: 21–8PubMed

17.

Kost RG, Hill EL, Tigges M, et al. Recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N Engl J Med 1993; 329: 1777–82PubMedCrossRef

18.

Mouly F, Baccard M, Scieux C, et al. Chronic recurrent acyclovir-resistant genital herpes in an immunocompetent patient [letter]. Dermatology 1995; 190: 177PubMedCrossRef

19.

Setter SM, Hill EL, Kern ER, et al. Chronic vulvar ulceration in an immunocompetent woman due to acyclovir-resistant, thymidine kinase-deficient herpes simplex virus. J Infect Dis 1998; 1777: 543–50CrossRef

20.

Kriesel, JD, Spruance L, Parker JN, et al. Recurrent antiviral-resistant genital herpes in an immunocompetent patient. J Infect Dis 2005; 192: 156–61PubMedCrossRef

21.

Englund JA, Zimmerman ME, Swierkosz EM, et al. Herpes simplex virus resistant to acyclovir: a study in a tertiary care center. Ann Intern Med 1990; 112: 416–22PubMed

22.

Crumpacker CS, Schnipper LE, Marlowe SI, et al. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med 1982; 306: 343–6PubMedCrossRef

23.

Burns WH, Saral R, Santos GW, et al. Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy. Lancet 1982; 1(8269): 421–3PubMedCrossRef

24.

Wade JC, McLaren C, Meyers JD. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple course of treatment with acyclovir. J Infect Dis 1983; 148: 1077–82PubMedCrossRef

25.

Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320: 293–6PubMedCrossRef

26.

Chilukuri S, Rosen T. Management of aciclovir-resistant herpes simplex virus. Dermatol Clin 2003; 21: 311–30PubMed

27.

Engel JP, Englund JA, Fletcher CV, et al. Treatment of resistant-herpes simplex virus with continuous-infusion aciclovir. JAMA 1990. 263(12): 1662–4PubMedCrossRef

28.

Fletcher CV, Englund JA, Bean B, et al. Continuous infusion of high-dose aciclovir for serious herpesvirus infections. Antimicrob Agents Chemother 1989; 33: 1375–8PubMedCrossRef

29.

Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for aciclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med 1991; 325: 551–5PubMedCrossRef

30.

Stewart JA, Reef SE, Pellett PE, et al. Herpesvirus infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21Suppl. 1: S114–20PubMedCrossRef

31.

Tyring S, Engst R, Corriveau C, et al. Famciclovir for ophthalmic zoster; a randomised aciclovir controlled study. Br J Ophthalmol 2001; 85: 576–81PubMedCrossRef

32.

Tyring SK, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valaciclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000; 9: 863–9PubMedCrossRef

33.

Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrobial Agents Chemother 1994; 38: 2454–7CrossRef

Titel: Famciclovir for the Management of Genital Herpes Simplex in Patients with Inadequate Response to Aciclovir or Valaciclovir
verfasst von: Stephen L. Sacks
Dr Fred Y. Aoki
Publikationsdatum: 01.12.2005
Verlag: Springer International Publishing
Erschienen in: Clinical Drug Investigation / Ausgabe 12/2005
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI: https://doi.org/10.2165/00044011-200525120-00006

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Famciclovir for the Management of Genital Herpes Simplex in Patients with Inadequate Response to Aciclovir or Valaciclovir

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2005

Insomnia in General Practice

Economic Evaluation of Tramadol/ Paracetamol Combination Tablets for Osteoarthritis Pain in The Netherlands

Acknowledgement

Effects of Cilnidipine on Fibrinolysis in Chinese Hypertensive Patients

Antihypertensive Effect of Irbesartan and Predictors of Response in Obesity- Associated Hypertension